Sana Biotechnology (SANA) Price & Analysis

Compare

853 Followers

SANA Stock Chart & Stats

$3.27

$3.38(204.85%)

At close: Jan 08 4:00 PM EST

$3.27

$3.38(204.85%)

Day’s Range― - ―

52-Week Range$1.26 - $6.55

Previous CloseN/A

Volume118.31M

Average Volume (3M)2.26M

Market Cap

$872.65M

Enterprise Value$866.30M

Total Cash (Recent Filing)$138.38M

Total Debt (Recent Filing)$78.86M

Price to Earnings (P/E)―

Beta1.32

Next Earnings

May 13, 2026

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding266,866,880

10 Day Avg. Volume3,053,012

30 Day Avg. Volume2,263,124

Financial Highlights & Ratios

PEG Ratio0.24

Price to Book (P/B)6.41

Price to Sales (P/S)0.00

P/FCF Ratio-7.12

Enterprise Value/Market Cap0.99

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-283.75

Enterprise Value/Ebitda-4.73

Forecast

1Y Price Target

$9.50

Price Target Upside190.52% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.64

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Durability Of Islet TherapyDurable function observed in HIP‑modified pancreatic islet cells with a rebound in C‑peptide suggests continued survival and ongoing insulin production from the graft.

In Vivo CAR‑T Commercial PotentialSG293's in vivo edited CD19 CAR‑T approach and preclinical data showing targeted B‑cell depletion without conditioning point to a potential one‑time, off‑the‑shelf therapy that could simplify delivery and lower costs versus autologous CAR‑T products.

Regulatory And Manufacturing EnablementA GMP‑grade master cell bank established for the SC451 program supports completion of GLP toxicology work and positions the program for an eventual IND filing once manufacturing is transferred to a GMP facility.

Bears Say

Clinical Signal UncertaintyMultiple non‑immune factors such as obesity, diet, and insulin resistance can affect C‑peptide readings, making it unclear whether observed fluctuations reflect true graft performance.

Financial Runway And Balance Sheet ExposureThe company reported a substantial net loss and a finite cash runway, with non‑cash charges tied to contingent success‑payment liabilities highlighting risk of needing additional financing.

Waning Graft Function RiskDecreasing C‑peptide measurements in the UP421 patient indicate possible waning graft function that could limit long‑term efficacy of the cell therapy.

Sana Biotechnology News

Sana announces follow-up results from first-in-human study transplanting UP421

Sana Biotechnology (SANA) announced 14-month follow-up results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet...

5d ago

SANA

Sana Biotechnology files automatic mixed securities shelf

17:22 EST Sana Biotechnology (SANA) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

15d ago

SANA

Sana Biotechnology reports Q4 EPS (16c), consensus (13c)

Cash, cash equivalents, and marketable securities as of December 31, 2025 were $138.4M compared to $152.5M as of...

15d ago

SANA

Sana Biotechnology appoints Piper as EVP, CFO

Sana Biotechnology (SANA) announced the appointment of Brian Piper as Executive Vice President, EVP, Chief Financial Officer, CFO....

29d ago

SANA

Durable HIP Technology Data De‑Risks Sana Biotechnology’s SC451 Program and Supports Buy Rating

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Sana Biotechnology today and set a price target...

5d ago

SANA

Sana Biotechnology: Advancing T1D and In Vivo CAR-T Programs with 2026 Catalysts and Solid Cash Runway Supporting Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on SANA stock, giving a Buy rating today....

12d ago

SANA

AI Adoption Exposes Sana Biotechnology to Rising Data, Compliance, and Reputational Risks

Sana Biotechnology, Inc. (SANA) has disclosed a new risk, in the Technology category. Sana Biotechnology, Inc. faces material...

13d ago

SANA

Sana Biotechnology: Emerging Clinical Validation and 2026 Pivotal Milestones Underpin Buy Rating

Sana Biotechnology, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from...

14d ago

SANA

Sana Biotechnology Updates ATM Program to Support Development

Sana Biotechnology ( ($SANA) ) just unveiled an update. Sana Biotechnology, Inc., based in Seattle and listed on...

15d ago

SANA

Sana Biotechnology Names Brian Piper as New CFO

Sana Biotechnology ( ($SANA) ) has issued an update. On February 17, 2026, Sana Biotechnology appointed Brian Piper...

29d ago

SANA

Sana Biotechnology Highlights Diabetes Cell Therapy Advances at Conference

Sana Biotechnology ( ($SANA) ) has issued an update. At the 44th Annual J.P. Morgan Healthcare Conference on...

2M ago

SANA

Sana Biotechnology price target raised to $7 from $6 at BofA

BofA raised the firm’s price target on Sana Biotechnology (SANA) to $7 from $6 and keeps a Buy...

2M ago

SANA

Sana Biotechnology announces publication of in vivo gene editing

Sana Biotechnology (SANA) announced that Nature Biotechnology has published a journal article titled “In vivo gene editing of...

3M ago

SANA

Sana Biotechnology’s Strategic Focus on T1D Therapies Justifies Buy Rating

H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating on Sana Biotechnology today and set a price target...

4M ago

SANA

SANA FAQ

What was Sana Biotechnology’s price range in the past 12 months?

Sana Biotechnology lowest stock price was $1.26 and its highest was $6.55 in the past 12 months.

What is Sana Biotechnology’s market cap?

Sana Biotechnology’s market cap is $872.65M.

When is Sana Biotechnology’s upcoming earnings report date?

Sana Biotechnology’s upcoming earnings report date is May 13, 2026 which is in 56 days.

How were Sana Biotechnology’s earnings last quarter?

Sana Biotechnology released its earnings results on Mar 03, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.068.

Is Sana Biotechnology overvalued?

According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sana Biotechnology pay dividends?

Sana Biotechnology does not currently pay dividends.

What is Sana Biotechnology’s EPS estimate?

Sana Biotechnology’s EPS estimate is -0.16.

How many shares outstanding does Sana Biotechnology have?

Sana Biotechnology has 266,866,880 shares outstanding.

What happened to Sana Biotechnology’s price movement after its last earnings report?

Sana Biotechnology reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -2.799%.

Which hedge fund is a major shareholder of Sana Biotechnology?

Currently, no hedge funds are holding shares in SANA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sana Biotechnology Stock Smart Score

Neutral

Fundamentals

Return on Equity

-141.99%

Trailing 12-Months

Asset Growth

-14.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sana Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology (SANA) Earnings & Revenues

Historic Earnings Reports

SANA Stock 12 Month Forecast

Average Price Target

$9.50

▲(190.52% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.15,4.753846153846154,5.357692307692308,5.961538461538462,6.565384615384616,7.1692307692307695,7.773076923076923,8.376923076923077,8.98076923076923,9.584615384615384,10.188461538461539,10.792307692307691,11.396153846153846,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.15,4.561538461538462,4.973076923076923,5.384615384615385,5.796153846153846,6.207692307692308,6.61923076923077,7.030769230769231,7.4423076923076925,7.853846153846154,8.265384615384615,8.676923076923078,9.088461538461539,{"y":9.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.15,4.36923076923077,4.588461538461539,4.807692307692308,5.026923076923077,5.246153846153846,5.4653846153846155,5.684615384615385,5.903846153846154,6.123076923076923,6.342307692307692,6.561538461538461,6.780769230769231,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.63,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >